A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

Columnist Kylene Henderson and her husband, Donnie, who has PF, swapped caregiver roles after Kylene was injured in a recent ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google First in a series. If you’ve read my previous columns, you’ll ...

With chronic kidney disease a risk for transplant recipients, columnist Sam Kirton writes about the need for more living kidney donors.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...